CFTR Modulators Correct Protein Trafficking for Cystic Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly those targeting the F508del mutation in the CFTR gene, are inadequate in effectively addressing the severe forms of the disease, as they fail to adequately correct protein folding and trafficking, leading to insufficient anion and fluid transport in epithelial cells.
Innovation Solution
Development of novel compounds containing silicon or germanium atoms, such as those represented by Formulas (1), (2), (3), and (4), which act as CFTR modulators to correct protein trafficking and enhance channel activity, thereby improving anion and fluid transport across epithelial membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CFTR modulators are used to treat F508del mutation, then some anion transport function is restored, but protein folding and trafficking are not adequately corrected, resulting in insufficient therapeutic effect
Solution Approach 1:
The patent employs a combination of two distinct CFTR modulators (a corrector and a potentiator) in a single pharmaceutical composition. The corrector component addresses protein folding and trafficking defects, while the potentiator component enhances channel gating function. This composite approach simultaneously corrects multiple aspects of CFTR dysfunction that single agents cannot address alone, thereby improving overall therapeutic reliability for F508del mutation.
Solution Approach 2:
The therapeutic approach is divided into two functional segments: a corrector segment that specifically targets protein folding and trafficking defects in the endoplasmic reticulum and Golgi apparatus, and a potentiator segment that enhances channel opening probability and conductance at the plasma membrane. This segmentation allows each component to optimize its specific function while working synergistically to achieve comprehensive therapeutic effect.
2Productivity
If CFTR modulators are administered to increase channel activity, then anion transport improves, but the number of functional channels at the cell surface remains insufficient due to trafficking defects
Solution Approach 1:
The corrector component acts preliminarily by facilitating proper CFTR protein folding and enabling successful trafficking from the endoplasmic reticulum through the Golgi apparatus to the plasma membrane. This preliminary correction of protein conformation and cellular transport must occur before the potentiator can effectively enhance channel function. The sequential action ensures sufficient channels reach the cell surface before maximizing their activity.
Solution Approach 2:
The patent merges two mechanisms of action into a single therapeutic regimen: the corrector's ability to increase the number of channels reaching the plasma membrane by fixing trafficking defects, and the potentiator's ability to increase the activity of each individual channel. This combination simultaneously addresses both the quantity and quality aspects of CFTR function, achieving synergistic improvement in overall anion transport capacity.
3Ease of operation
If single-agent CFTR modulators are used, then treatment is simpler, but they cannot adequately address both protein folding and channel gating defects
Solution Approach 1:
The pharmaceutical composition is designed with multi-functionality to address diverse CFTR defects within a single treatment protocol. The corrector component handles protein folding and trafficking issues, while the potentiator component addresses channel gating defects. This universal approach allows the same composition to effectively treat the complex, multi-faceted pathology of F508del mutation without requiring separate targeted therapies for different defect types.
Data Source
AI summary
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.